36 results on '"Chi, Kim N"'
Search Results
2. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
- Author
-
Herberts, Cameron, Annala, Matti, Sipola, Joonatan, Ng, Sarah W. S., Chen, Xinyi E., Nurminen, Anssi, Korhonen, Olga V., Munzur, Aslı D., Beja, Kevin, Schönlau, Elena, Bernales, Cecily Q., Ritch, Elie, Bacon, Jack V. W., Lack, Nathan A., Nykter, Matti, Aggarwal, Rahul, Small, Eric J., Gleave, Martin E., Quigley, David A., Feng, Felix Y., Chi, Kim N., and Wyatt, Alexander W.
- Abstract
Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer genotyping and longitudinal disease monitoring1. However, owing to past emphasis on targeted and low-resolution profiling approaches, our understanding of the distinct populations that comprise bulk ctDNA is incomplete2–12. Here we perform deep whole-genome sequencing of serial plasma and synchronous metastases in patients with aggressive prostate cancer. We comprehensively assess all classes of genomic alterations and show that ctDNA contains multiple dominant populations, the evolutionary histories of which frequently indicate whole-genome doubling and shifts in mutational processes. Although tissue and ctDNA showed concordant clonally expanded cancer driver alterations, most individual metastases contributed only a minor share of total ctDNA. By comparing serial ctDNA before and after clinical progression on potent inhibitors of the androgen receptor (AR) pathway, we reveal population restructuring converging solely on ARaugmentation as the dominant genomic driver of acquired treatment resistance. Finally, we leverage nucleosome footprints in ctDNA to infer mRNA expression in synchronously biopsied metastases, including treatment-induced changes in AR transcription factor signalling activity. Our results provide insights into cancer biology and show that liquid biopsy can be used as a tool for comprehensive multi-omic discovery.
- Published
- 2022
- Full Text
- View/download PDF
3. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer
- Author
-
Heng, Daniel Y.C., Chi, Kim N., Murray, Nevin, Jin, Tao, Garcia, Jorge A., Bukowski, Ronald M., Rini, Brian I., and Kollmannsberger, Christian
- Subjects
Carcinoma, Renal cell -- Dosage and administration ,Carcinoma, Renal cell -- Patient outcomes ,Carcinoma, Renal cell -- Research ,Vascular endothelial growth factor -- Physiological aspects ,Vascular endothelial growth factor -- Research ,Health - Published
- 2009
4. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial
- Author
-
Beer, Tomasz M., Lalani, Alshad S., Lee, Stella, Mori, Motomi, Eilers, Kristine M., Curd, John G., Henner, W. David, Ryan, Christopher W., Venner, Peter, Ruether, J. Dean, and Chi, Kim N.
- Subjects
C-reactive protein -- Analysis ,Tumor markers -- Research ,Prostate cancer -- Patient outcomes ,Prostate cancer -- Research ,Prognosis -- Research ,Health - Published
- 2008
5. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel
- Author
-
Beer, Tomasz M., Ryan, Christopher W., Venner, Peter M., Petrylak, Daniel P., Chatta, Gurkamal S., Ruether, J. Dean, Chi, Kim N., Young, James, and Henner, W. David
- Subjects
Prostate cancer -- Care and treatment ,Calcitriol -- Dosage and administration ,Docetaxel -- Dosage and administration ,Chemotherapy -- Patient outcomes ,Chemotherapy -- Research ,Oncology, Experimental -- Reports ,Cancer -- Chemotherapy ,Cancer -- Patient outcomes ,Cancer -- Research ,Cancer -- Reports ,Health - Published
- 2008
6. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer
- Author
-
Sonpavde, Guru, Chi, Kim N., Powles, Thomas, Sweeney, Christopher J., Hahn, Noah, Hutson, Thomas E., Galsky, Matthew D., Berry, William R., and Kadmon, Dov
- Subjects
Neoadjuvant therapy -- Research ,Prostate cancer -- Care and treatment ,Prostatectomy -- Usage ,Prostatectomy -- Patient outcomes ,Prostatectomy -- Research ,Combined modality therapy -- Patient outcomes ,Combined modality therapy -- Research ,Health - Published
- 2007
7. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer
- Author
-
Chi, Kim N., Eisenhauer, Elizabeth, Fazli, Ladan, Jones, Edward C., Goldenberg, S. Larry, Powers, Jean, Tu, Dongsheng, and Gleave, Martin E.
- Subjects
Molecular chaperones -- Research ,Prostate cancer -- Risk factors ,Prostate cancer -- Care and treatment ,Cancer -- Research ,Oncology, Experimental ,Health - Abstract
Background: Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment resistance. OGX-011 is a 2'-methoxyethyl modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA and has been reported to inhibit clusterin expression and enhance drug efficacy in xenograft models. The primary objective of this clinical study was to determine a biologically effective dose of OGX-011 that would inhibit clusterin expression in human cancer. Methods: Subjects (n = 25) with localized prostate cancer with high-risk features who were candidates for prostatectomy were treated with OGX-011 by 2-hour intravenous infusion on days 1, 3, and 5 and then weekly from days 8-29 combined with androgen blockade starting on day 1; prostatectomy was performed on days 30-36. Six different doses were tested, from 40 to 640 mg. OGX-011 plasma and prostate tissue concentrations were measured by an enzyme-linked immunosorbent assay method, and the pharmacokinetics of OGX-011 were determined from these data. Prostate cancer tissue, lymph nodes, and serial samples of peripheral blood mononuclear cells were assessed for clusterin expression using quantitative real-time polymerase chain reaction and immunohistochemistry. All statistical tests were two-sided. Results: Only grade 1 and 2 toxicities were observed. The plasma half-life of OGX-011 was approximately 2-3 hours, and the area under the concentration versus time curve and [C.sub.MAX] (peak plasma concentration) increased proportionally with dose ([P.sub.trend]
- Published
- 2005
8. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
- Author
-
Sweeney, Christopher, Bracarda, Sergio, Sternberg, Cora N, Chi, Kim N, Olmos, David, Sandhu, Shahneen, Massard, Christophe, Matsubara, Nobuaki, Alekseev, Boris, Parnis, Francis, Atduev, Vagif, Buchschacher, Gary L, Gafanov, Rustem, Corrales, Luis, Borre, Michael, Stroyakovskiy, Daniil, Alves, Gustavo Vasconcelos, Bournakis, Evangelos, Puente, Javier, Harle-Yge, Marie-Laurence, Gallo, Jorge, Chen, Geng, Hanover, Justin, Wongchenko, Matthew J, Garcia, Josep, and de Bono, Johann S
- Abstract
The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss status have hyperactivated AKT signalling. Dual pathway inhibition with AKT inhibitor ipatasertib plus abiraterone might have greater benefit than abiraterone alone. We aimed to compare ipatasertib plus abiraterone with placebo plus abiraterone in patients with previously untreated mCRPC with or without tumour PTEN loss.
- Published
- 2021
- Full Text
- View/download PDF
9. Clinical implications of genomic alterations in metastatic prostate cancer
- Author
-
Sumiyoshi, Takayuki, Chi, Kim N., and Wyatt, Alexander W.
- Abstract
There has been a rapid expansion in treatment options for the management of metastatic prostate cancer, but individual patient outcomes can be variable due to inter-patient tumor heterogeneity. Fortunately, the disease can be stratified on the basis of common somatic features, providing potential for the development of clinically useful prognostic and predictive biomarkers. Tissue biopsy programs and studies leveraging circulating tumor DNA (ctDNA) have revealed specific genomic alterations that are associated with aggressive disease biology. In this review, we discuss the potential for genomic subtyping to improve prognostication and to help guide treatment selection. We summarize data on associations between ARpathway alterations and patient response to AR signaling inhibitors and other standards of care. We describe the links between detection of different types of DNA damage repair defects and clinical outcomes with targeted therapies such as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors or immune checkpoint inhibitors. PI3K signaling pathway inhibitors are also in advanced clinical development and we report upon the potential for these and other novel targeted therapies to have impact in specific molecular subsets of metastatic prostate cancer. Finally, we discuss the growing use of blood-based analytes for prognostic and predictive biomarker development, and summarize ongoing prospective biomarker-driven clinical trials.
- Published
- 2021
- Full Text
- View/download PDF
10. A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer
- Author
-
Sridhar, Srikala S., Joshua, Anthony M., Gregg, Richard, Booth, Christopher M., Murray, Nevin, Golubovic, Jovana, Wang, Lisa, Harris, Pamela, and Chi, Kim N.
- Abstract
In this Phase 2 study, the angiogenesis inhibitor pazopanib was tested alone and in combination with bicalutamide in castration resistant prostate cancer. Not enough patients showed PSA responses to indicate this is an effective treatment. A few patients however did show benefit, suggesting further study is needed to understand why these patients responded but others did not.
- Published
- 2024
- Full Text
- View/download PDF
11. Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial
- Author
-
Sridhar, Srikala S., Blais, Normand, Tran, Ben, Reaume, M. Neil, North, Scott A., Stockler, Martin R., Chi, Kim N., Fleshner, Neil E., Liu, Geoffrey, Robinson, John W., Mukherjee, Som D., Rahim, Yasmin, Winquist, Eric, Booth, Christopher M., Nguyen, Nghia Trung, Beardsley, Emma K., Alimohamed, Nimira S., McDonald, Gail T., Ding, Keyue, and Parulekar, Wendy R.
- Abstract
IMPORTANCE: Treatment options for platinum-refractory metastatic urothelial cancer (mUC) are limited, and outcomes remain poor. Nab-paclitaxel is an albumin-bound formulation of paclitaxel showing promising activity and tolerability in a prior single-arm trial. OBJECTIVES: To evaluate the efficacy and safety of nab-paclitaxel vs paclitaxel in platinum-refractory mUC. DESIGN, SETTING, AND PARTICIPANTS: In this investigator-initiated, open-label, phase 2 randomized clinical trial conducted across Canada and Australia from January 2014 to April 2017, eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract. Mixed histologic findings, except small cell, were permitted provided UC was the predominant histologic finding. All patients had received platinum-based chemotherapy either in the metastatic setting or were within 12 months of perioperative chemotherapy. Patients with prior taxane chemotherapy were not included. Patients had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 to 2 and adequate organ function. INTERVENTIONS: Patients were randomized to nab-paclitaxel, 260 mg/m2, or paclitaxel, 175 mg/m2, every 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS). RESULTS: Among 199 patients, median age was 67 (range, 24-88) years; 144 (72%) were men; 167 (84%) were ECOG PS 0-1; 59 (30%) had liver metastases; and 110 (55%) were within 6 months of prior platinum-based chemotherapy. At a median follow-up of 16.4 months, there was no significant difference between nab-paclitaxel vs paclitaxel for median PFS (3.4 months vs 3.0 months; hazard ratio [HR], 0.92; 90% CI, 0.68-1.23; 1-sided P = .31). Median overall survival was 7.5 months for nab-paclitaxel vs 8.8 months for paclitaxel (HR, 0.95; 90% CI, 0.70-1.30; 1-sided P = .40); and objective response rate (ORR) was 22% for nab-paclitaxel vs 25% for paclitaxel (P = .97). Grade 3/4 adverse events were more frequent with nab-paclitaxel (64/97 [66%]) compared with paclitaxel (45/97 [46%]), P = .009; but peripheral sensory neuropathy was similar (all grades, 72/97 [74%] vs 64/97 [66%]; grade 3/4, 7/97 [7%] vs 3/97 [3%]; P = .27). There were no apparent differences in scores for health-related quality of life. CONCLUSIONS AND RELEVANCE: In this open-label, phase 2 randomized clinical trial of patients with platinum-refractory mUC, nab-paclitaxel had similar efficacy to paclitaxel; but worse toxic effects. The ORR with either taxane, however, was higher than previously reported and similar to those reported for the immune checkpoint inhibitors, suggesting that the taxanes remain a reasonable option in this setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02033993
- Published
- 2020
- Full Text
- View/download PDF
12. The DNA methylation landscape of advanced prostate cancer
- Author
-
Zhao, Shuang G., Chen, William S., Li, Haolong, Foye, Adam, Zhang, Meng, Sjöström, Martin, Aggarwal, Rahul, Playdle, Denise, Liao, Arnold, Alumkal, Joshi J., Das, Rajdeep, Chou, Jonathan, Hua, Junjie T., Barnard, Travis J., Bailey, Adina M., Chow, Eric D., Perry, Marc D., Dang, Ha X., Yang, Rendong, Moussavi-Baygi, Ruhollah, Zhang, Li, Alshalalfa, Mohammed, Laura Chang, S., Houlahan, Kathleen E., Shiah, Yu-Jia, Beer, Tomasz M., Thomas, George, Chi, Kim N., Gleave, Martin, Zoubeidi, Amina, Reiter, Robert E., Rettig, Matthew B., Witte, Owen, Yvonne Kim, M., Fong, Lawrence, Spratt, Daniel E., Morgan, Todd M., Bose, Rohit, Huang, Franklin W., Li, Hui, Chesner, Lisa, Shenoy, Tanushree, Goodarzi, Hani, Asangani, Irfan A., Sandhu, Shahneen, Lang, Joshua M., Mahajan, Nupam P., Lara, Primo N., Evans, Christopher P., Febbo, Phillip, Batzoglou, Serafim, Knudsen, Karen E., He, Housheng H., Huang, Jiaoti, Zwart, Wilbert, Costello, Joseph F., Luo, Jianhua, Tomlins, Scott A., Wyatt, Alexander W., Dehm, Scott M., Ashworth, Alan, Gilbert, Luke A., Boutros, Paul C., Farh, Kyle, Chinnaiyan, Arul M., Maher, Christopher A., Small, Eric J., Quigley, David A., and Feng, Felix Y.
- Abstract
Although DNA methylation is a key regulator of gene expression, the comprehensive methylation landscape of metastatic cancer has never been defined. Through whole-genome bisulfite sequencing paired with deep whole-genome and transcriptome sequencing of 100 castration-resistant prostate metastases, we discovered alterations affecting driver genes that were detectable only with integrated whole-genome approaches. Notably, we observed that 22% of tumors exhibited a novel epigenomic subtype associated with hypermethylation and somatic mutations in TET2, DNMT3B, IDH1and BRAF. We also identified intergenic regions where methylation is associated with RNA expression of the oncogenic driver genes AR, MYCand ERG. Finally, we showed that differential methylation during progression preferentially occurs at somatic mutational hotspots and putative regulatory regions. This study is a large integrated study of whole-genome, whole-methylome and whole-transcriptome sequencing in metastatic cancer that provides a comprehensive overview of the important regulatory role of methylation in metastatic castration-resistant prostate cancer.
- Published
- 2020
- Full Text
- View/download PDF
13. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer
- Author
-
Chen, William S., Feng, Eric L., Aggarwal, Rahul, Foye, Adam, Beer, Tomasz M., Alumkal, Joshi J., Gleave, Martin, Chi, Kim N., Reiter, Robert E., Rettig, Matthew B., Evans, Christopher P., Small, Eric J., Sharifi, Nima, and Zhao, Shuang G.
- Abstract
Introduction: Germline variants in androgen metabolism genes may influence clinical response to androgen deprivation therapy (ADT) in advanced prostate cancer. We sought to investigate the prognostic significance of germline variants in androgen metabolism genes with respect to overall survival (OS) after ADT, and to associate germline variants with tumor genomic features. Methods: Germline and somatic whole-genome sequencing (WGS) data were evaluated in a cohort of 101 men with metastatic castration-resistant prostate cancer (mCRPC). Survival analyses were performed to identify polymorphisms associated with impaired OS after primary ADT. Germline variants found to be prognostic of OS were associated with tumor somatic DNA-sequence alterations based on WGS performed on paired metastasis biopsies from the same 101 patients. Gene set enrichment analysis was performed based on tumor RNA-sequencing data to identify genomic pathways differentially expressed in patients with germline variants. Results: A comprehensive literature review identified 17 candidate polymorphisms in nine androgen metabolism genes that have been previously shown to have an association with response to ADT in prostate cancer. Of these, the variant rs1856888 allele located 13 kb upstream of HSD3B1was found to be significantly associated with impaired OS (P= 0.029). Variant rs1856888 was commonly co-inherited with the well-characterized HSD3B1(1245A>C) polymorphism, and there was a trend toward shorter median OS in patients with HSD3B1(1245A>C) compared with homozygous wild-type patients (P= 0.052). While HSD3B1germline variants were not associated with common somatic tumor DNA alterations, they were associated with increased tumor expression of cell proliferation and cell cycle genes. Conclusions: This study presents a comprehensive assessment of germline variants in androgen metabolism genes and highlights HSD3B1polymorphisms as prognostic of OS after ADT and associated with an aggressive gene expression tumor profile in mCRPC.
- Published
- 2020
- Full Text
- View/download PDF
14. Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial
- Author
-
Drakaki, Alexandra, Kirby, Conor J., van der Heijden, Michiel S., Petrylak, Daniel P., Powles, Thomas, Chi, Kim N., Fléchon, Aude, Necchi, Andrea, Géczi, Lajos, Lee, Jae-Lyun, Gakis, Georgios, Bracarda, Sergio, Chowdhury, Simon, Lin, Chia-Chi, Keizman, Daniel, Vaishampayan, Ulka N., Zimmermann, Annamaria H., Bell-McGuinn, Katherine, and Castellano, Daniel
- Abstract
The phase 3 RANGE trial found ramucirumab/docetaxel improved progression-free survival (PFS) versus placebo/docetaxel (median 4.1 vs 2.8 months; hazard ratio [HR] = 0.757, p = 0.0118) for treatment of platinum-refractory metastatic urothelial carcinoma (UC). Some patients received an immune checkpoint inhibitor (ICI) prior to RANGE. In other studies, unselected patients with platinum-refractory UC exhibited an overall response rate (ORR) of 15–31% to ICIs. Efficacy and safety data from the subgroup of patients treated with prior ICI were examined using prespecified analyses to compare outcomes between RANGE treatment arms. Randomized, double-blind RANGE study (n = 530) took place July 2015-April 2017 in 23 countries. Forty-five patients (8.5%) received prior ICI. PFS was evaluated using the Kaplan-Meier method and unstratified Cox proportional hazards model. 17 ramucirumab/docetaxel arm, 28 placebo/docetaxel arm patients were treated with an ICI. The prior-ICI ramucirumab subgroup had worse Bellmunt scores at baseline versus placebo (score of 2-3 : 70.6% vs 25%, respectively). Most patients (84.4%) received the ICI immediately following platinum and immediately prior to RANGE. ORR to prior ICI was 6.7% Responses were achieved by 5/17 (29.4%) on ramucirumab/docetaxel, compared to 2/28 (7.1%) on placebo/docetaxel. Median PFS was 3.15 months on ramucirumab/docetaxel versus 2.73 months on placebo/docetaxel (HR = 0.786, 95% CI = 0.404–1.528, p = 0.4877). The frequency of grade≥3 adverse events was similar between arms. Limitations include sample size and treatment setting of the analyzed population. Ramucirumab/docetaxel may provide a clinical benefit with acceptable safety in the third-line setting for metastatic UC patients whose disease has progressed on both prior platinum chemotherapy and ICI therapy.
- Published
- 2020
- Full Text
- View/download PDF
15. Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy
- Author
-
Harsini, Sara, Wilson, Don, Saprunoff, Heather, Allan, Hayley, Gleave, Martin, Goldenberg, Larry, Chi, Kim N., Kim-Sing, Charmaine, Tyldesley, Scott, and Bénard, François
- Abstract
Background: Radiotherapy (RT) and surgery are potential treatment options in patients with biochemical recurrence (BCR) following primary prostate cancer treatment. This study examines the value of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-informed surgery and RT in patients with BCR treated without systemic therapy. Methods: This is a post-hoc subgroup analysis of a prospective clinical trial. Inclusion criteria were: histologically proven prostate cancer at initial curative-intent treatment, BCR after primary treatment with curative intent, having five or fewer lesions identified on [
18 F]DCFPyL PET/CT, and treatment with either PET/CT-directed RT or surgery without systemic therapy. The biochemical progression-free survival after PSMA ligand PET/CT-directed RT and surgery was determined. Uni- and multivariate Cox regression analyses were performed for the association of patients’ characteristics, tumor-specific variables, and PSMA PET/CT imaging results with biochemical progression at the last follow-up. Results: Fifty-eight patients (30 in surgery and 28 in radiotherapy groups) met the inclusion criteria. A total of 87 PSMA-positive lesions were detected: 16 local recurrences (18.4%), 54 regional lymph nodes (62.1%), 6 distant lymph nodes (6,8%), and 11 osseous lesions (12.7%). A total of 85.7% (24 of 28) and 70.0% (21 of 30) of patients showed a ≥ 50% decrease in prostate-specific antigen (PSA) levels after RT and surgery, respectively. At a median follow-up time of 21 months (range, 6–32 months), the median biochemical progression-free survival was 19 months (range, 4 to 23 months) in the radiotherapy group, as compared with 16.5 months (range, 4 to 28 months) in the surgery group. On multivariate Cox regression analysis, the number of PSMA positive lesions (2–5 lesions compared to one lesion), and the anatomic location of the detected lesions (distant metastasis vs. local relapse and pelvic nodal relapse) significantly correlated with biochemical progression at the last follow-up, whereas other clinical, tumor-specific, and imaging parameters did not. Conclusions: This study suggests that RT or surgery based on [18 F]DCFPyL PET/CT are associated with high PSA response rates. The number and site of lesions detected on the PSMA PET/CT were predictive of biochemical progression on follow-up. Further studies are needed to assess the impact of targeting these sites on patient relevant outcomes. Trial registration: Registered September 14, 2016; NCT02899312;https://clinicaltrials.gov/ct2/show/NCT02899312 - Published
- 2023
- Full Text
- View/download PDF
16. Managing CRPC: improving symptoms, survival, or both?
- Author
-
Chi, Kim N.
- Subjects
Prostate cancer -- Patient outcomes ,Metastasis -- Patient outcomes ,Cancer -- Care and treatment ,Company business management ,Health - Abstract
Managing CRPC: Improving Symptoms, Survival, or Both? Until recently, available systemic therapy with proven efficacy for metastatic castration-resistant prostate cancer (CRPC) consisted of mitoxantrone (Novantrone), [1] docetaxel, [2] and zoledronic [...]
- Published
- 2011
17. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer
- Author
-
Sumanasuriya, Semini, Omlin, Aurelius, Armstrong, Andrew, Attard, Gerhardt, Chi, Kim N., Bevan, Charlotte L., Shibakawa, Aki, IJzerman, Maarten J., De Laere, Bram, Lolkema, Martijn, Lorente, David, Luo, Jun, Mehra, Niven, Olmos, David, Scher, Howard, Soule, Howard, Stoecklein, Nikolas H., Terstappen, Leon W.M.M., Waugh, David, and de Bono, Johann S.
- Abstract
In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic monitoring and as prognostic and predictive biomarkers. However, there is a lack of consensus and standardisation regarding analyses, reporting, and integration of results into specific clinical contexts. A consensus meeting on circulating biomarkers was held to address these topics.
- Published
- 2018
- Full Text
- View/download PDF
18. The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer
- Author
-
Heinrich, Daniel, Bektic, Jasmin, Bergman, Andries M., Caffo, Orazio, Cathomas, Richard, Chi, Kim N., Daugaard, Gedske, Keizman, Daniel, Kindblom, Jon, Kramer, Gero, Olmos, David, Omlin, Aurelius, Sridhar, Srikala S., Tucci, Marcello, van Oort, Inge, and Nilsson, Sten
- Abstract
Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for patients treated with radium-223 and best standard of care (BSoC) when compared with placebo and BSoC in the ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial. At that time, docetaxel was the standard first-line choice for patients with metastatic CRPC (mCRPC). Since then, the treatment landscape has changed dramatically with new hormonal agents (abiraterone and enzalutamide) considered to be the first-line choice for many patients. The optimal patient profile for radium-223 in the modern setting, and its best use either in sequence or in combination with other approved agents are unclear, with few definitive guidelines available. This article reports on the views of a group of urologists and medical oncologists experienced in treating patients with mCRPC with radium-223 in routine clinical practice. The aim is to provide an overview of the current use of radium-223 in the treatment of patients with mCRPC, and to discuss best practices for patient selection and on-treatment monitoring. Where agreement was reached, guidance on the optimal use of radium-223 is provided.
- Published
- 2018
- Full Text
- View/download PDF
19. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
- Author
-
Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Hegemann, Miriam, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, del Muro, Xavier Garcia, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Widau, Ryan C, Liepa, Astra M, Walgren, Richard A, Hamid, Oday, Zimmermann, Annamaria H, Bell-McGuinn, Katherine M, Powles, Thomas, Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Ng, Siobhan Su Wan, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Chi, Kim Nguyen, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Laestadius, Fredrik, Joly, Florence, Flechon, Aude, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Gakis, Georgios, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Bamias, Aristotelis, Révész, Janos, Geczi, Lajos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Peer, Avivit, Sarid, David, Scagliotti, Giorgio Vittorio, Sternberg, Cora N, Tortora, Giampaolo, Bracarda, Sergio, Necchi, Andrea, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Matsubara, Nobuaki, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Jae-Lyun, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Cortés, Leticia Vazquez, Flores, Claudia Lorena Urzua, Blaisse, Reinoud J B, van der Heijden, Michiel S, de Wit, Ronald, Erdkamp, Fransiscus L G, Aarts, Maureen J B, Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Safina, Sufia Z, Alekseev, Boris, Semenov, Andrey, Fomkin, Roman, Pulido, Enrique Grande, Del Muro, F Xavier García, Mignorance, Juan Ignacio Delgado, Gauna, Daniel Castellano, Rodríguez-Vida, Alejo, Su, Yu-Li, Ou, Yen-Chuan, Lin, Chien-Liang, Su, Wen-Pin, Lin, Chia-Chi, Yeh, Su-Peng, Çiçin, Irfan, Harputluoglu, Hakan, Erman, Mustafa, Coskun, Hasan Senol, Urun, Yuksel, Golovko, Yurii, Bondarenko, Igor, Sinielnikov, Ivan, Powles, Thomas, Crabb, Simon, Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Drakaki, Alexandra, Flaig, Thomas, Pan, Chong Xian, Petrylak, Daniel, Schwarz, James, Percent, Ivor, Cultrera, Jennifer, Hainsworth, John, Herms, Benjamin, Lawler, William, Lowe, Thomas, Tagawa, Scott, Aragon-Ching, Jeanny, and Vaishampayan, Ulka
- Abstract
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab—a human IgG1 VEGFR-2 antagonist—or placebo in this patient population.
- Published
- 2017
- Full Text
- View/download PDF
20. Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer
- Author
-
Matsubara, Nobuaki, de Bono, Johann, Sweeney, Christopher, Chi, Kim N., Olmos, David, Sandhu, Shahneen, Massard, Christophe, Garcia, Josep, Chen, Geng, Harris, Adam, Schenkel, Fanny, Sane, Rucha, Hinton, Healther, Bracarda, Sergio, and Sternberg, Cora N.
- Abstract
•Adverse events (AEs) associated with ipatasertib plus abiraterone were manageable and reversible.•AEs appeared rapidly after the initiation of treatment and with limited recurrence.•Prophylactic measures can reduce the impact of AEs, as in other studies of ipatasertib.
- Published
- 2023
- Full Text
- View/download PDF
21. Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma
- Author
-
Annala, Matti, Nappi, Lucia, Azad, Arun A., Mo, Fan, Fazli, Ladan, Chi, Kim N., and Wyatt, Alexander W.
- Published
- 2017
- Full Text
- View/download PDF
22. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer
- Author
-
Small, Eric J., Chi, Kim N., Chowdhury, Simon, Bevans, Katherine B., Bhaumik, Amitabha, Saad, Fred, Ha Chung, Byung, Karsh, Lawrence I., Oudard, Stéphane, De Porre, Peter, Brookman-May, Sabine D., McCarthy, Sharon A., Mundle, Suneel D., Uemura, Hirotsugu, Smith, Matthew R., and Agarwal, Neeraj
- Abstract
At 3 and 6 mo of apalutamide treatment, patients with nonmetastatic and metastatic castration-resistant prostate cancer from SPARTAN and TITAN, who responded with a deep prostate-specific antigen decline, had prolonged time to worsening of health-related quality of life.
- Published
- 2023
- Full Text
- View/download PDF
23. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- Author
-
Wyatt, Alexander W., Azad, Arun A., Volik, Stanislav V., Annala, Matti, Beja, Kevin, McConeghy, Brian, Haegert, Anne, Warner, Evan W., Mo, Fan, Brahmbhatt, Sonal, Shukin, Robert, Le Bihan, Stephane, Gleave, Martin E., Nykter, Matti, Collins, Colin C., and Chi, Kim N.
- Abstract
IMPORTANCE: The molecular landscape underpinning response to the androgen receptor (AR) antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) is undefined. Consequently, there is an urgent need for practical biomarkers to guide therapy selection and elucidate resistance. Although tissue biopsies are impractical to perform routinely in the majority of patients with mCRPC, the analysis of plasma cell-free DNA (cfDNA) has recently emerged as a minimally invasive method to explore tumor characteristics. OBJECTIVE: To reveal genomic characteristics from cfDNA associated with clinical outcomes during enzalutamide treatment. DESIGN, SETTING, AND PARTICIPANTS: Plasma samples were obtained from August 4, 2013, to July 31, 2015, at a single academic institution (British Columbia Cancer Agency) from 65 patients with mCRPC. We collected temporal plasma samples (at baseline, 12 weeks, end of treatment) for circulating cfDNA and performed array comparative genomic hybridization copy number profiling and deep AR gene sequencing. Samples collected at end of treatment were also subjected to targeted sequencing of 19 prostate cancer–associated genes. EXPOSURE: Enzalutamide, 160 mg, daily orally. MAIN OUTCOMES AND MEASURES: Prostate-specific antigen response rate (decline ≥50% from baseline confirmed ≥3 weeks later). Radiographic (as per Prostate Cancer Working Group 2 Criteria) and/or clinical progression (defined as worsening disease-related symptoms necessitating a change in anticancer therapy and/or deterioration in Eastern Cooperative Group performance status ≥2 levels). RESULTS: The 65 patients had a median (interquartile range) age of 74 (68-79) years. Prostate-specific antigen response rate to enzalutamide treatment was 38% (25 of 65), while median clinical/radiographic progression-free survival was 3.5 (95% CI, 2.1-5.0) months. Cell-free DNA was isolated from 122 of 125 plasma samples, and targeted sequencing was successful in 119 of 122. AR mutations and/or copy number alterations were robustly detected in 48% (31 of 65) and 60% (18 of 30) of baseline and progression samples, respectively. Detection of AR amplification, heavily mutated AR (≥2 mutations), and RB1 loss were associated with worse progression-free survival, with hazard ratios of 2.92 (95% CI, 1.59-5.37), 3.94 (95% CI, 1.46-10.64), and 4.46 (95% CI, 2.28-8.74), respectively. AR mutations exhibited clonal selection during treatment, including an increase in glucocorticoid-sensitive AR L702H and promiscuous AR T878A in patients with prior abiraterone treatment. At the time of progression, cfDNA sequencing revealed mutations or copy number changes in all patients tested, including clinically actionable alterations in DNA damage repair genes and PI3K pathway genes, and a high frequency (4 of 14) of activating CTNNB1 mutations. CONCLUSIONS AND RELEVANCE: Clinically informative genomic profiling of cfDNA was feasible in nearly all patients with mCRPC and can provide important insights into enzalutamide response and resistance.
- Published
- 2016
- Full Text
- View/download PDF
24. Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer
- Author
-
Chedgy, Edmund C.P., Annala, Matti, Beja, Kevin, Warner, Evan W., Gleave, Martin E., Chi, Kim N., and Wyatt, Alexander W.
- Published
- 2016
- Full Text
- View/download PDF
25. Reply to neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer
- Author
-
Sonpavde, Guru, Garzotto, Mark, and Chi, Kim N.
- Subjects
Neoadjuvant therapy -- Research ,Prostate cancer -- Care and treatment ,Prostatectomy ,Health - Published
- 2008
26. Targeting heat shock proteins in metastatic castration-resistant prostate cancer
- Author
-
Azad, Arun A., Zoubeidi, Amina, Gleave, Martin E., and Chi, Kim N.
- Abstract
The survival of malignant cells is constantly threatened by a myriad of cellular insults. In the context of such proteotoxic stress, cancer cells activate cytoprotective adaptive pathways. Heat shock proteins (HSPs) are highly conserved molecular chaperones that are expressed at low levels under normal conditions, but upregulated by cellular stress. As molecular chaperones, HSPs control the stability and function of client proteins, preventing aggregation of misfolded proteins, facilitating intracellular protein trafficking, maintaining protein conformation to enable ligand binding, phosphorylating proteins in signalling complexes and degrading severely damaged proteins via the ubiquitin–proteasome pathway. A key client protein of several HSPs is the androgen receptor (AR). HSPs facilitate binding of dihydrotestosterone to the AR, and enhance AR-mediated transcriptional activity. The integral role of HSPs in AR function speaks to their potential utility as therapeutic targets in castration-resistant prostate cancer (CRPC), a disease state characterized by persistent activation of the androgen–AR axis. Inhibition of HSPs has the additional benefit of potentially modulating signalling and transcriptional networks that are associated with HSP client proteins in CRPC cells. As a consequence, HSPs represent highly attractive targets in the development of treatments for CRPC.
- Published
- 2015
- Full Text
- View/download PDF
27. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer
- Author
-
Chi, Kim N, Zoubeidi, Amina, and Gleave, Martin E
- Abstract
Background: Clusterin is a stress-induced cytoprotective chaperone protein, regulated by HSF1, and functions similarly to a small heat-shock protein. Clusterin is expressed in a variety of cancers and associated with broad-spectrum treatment resistance. Custirsen (OGX-011) is a 2′-methoxyethyl modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA; it is currently in clinical trials for patients with cancer. Objective/methods: To review the literature on the role of clusterin in cancer progression and treatment resistance, and to summarize completed and ongoing clinical trials with custirsen. Results/conclusions: Custirsen is well tolerated in humans and biologically active in inhibiting expression of clusterin in patients with cancer. Randomized trials of custirsen in combination with chemotherapy are planned in patients with castration-resistant prostate cancer.
- Published
- 2008
- Full Text
- View/download PDF
28. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer
- Author
-
Beardsley, Emma K and Chi, Kim N
- Abstract
There is an urgent need for systemic treatment options for patients with castration-resistant prostate cancer who have progressed after receiving first-line docetaxel chemotherapy. The purpose of this article is to review recent developments in this area.
- Published
- 2008
- Full Text
- View/download PDF
29. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer
- Author
-
Chi, Kim N., Chia, Stephen K., Dixon, Ross, Newman, Michael J., Wacher, Vince J., Sikic, Branimir, and Gelmon, Karen A.
- Abstract
Abstract Background: ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. Phase I trials of ONT-093 in normal human volunteers showed no dose-limiting toxicities at serum concentrations associated with biologic activity achieved with doses ranging from 300 to 500 mg. Methods: Phase I pharmacokinetic trial of ONT-093 in doses from 300 to 500 mg administered before and after intravenous paclitaxel doses of 150 to 175 mg/m2 repeated every 21 days. All patients received paclitaxel alone on cycle 1. Results: 18 patients were enrolled onto 4 dose levels. Toxicity of the combination included neutropenia, arthralgia, myalgia, and peripheral neuropathy. Four of 6 patients receiving 500 mg doses of ONT-093 and paclitaxel at 175 mg/m2 (dose level 4) had higher-grade neutropenia with cycle 2, with 1 patient experiencing febrile neutropenia. Plasma pharmacokinetic parameters of paclitaxel were unchanged between cycle 1 and 2 for dose levels 1 to 3, but at dose level 4, 45–65% increases in paclitaxel AUC were observed in 4 of the 6 patients. Mean Cmax of ONT-093 was 9 μM (range 5–15 μM) which were 3- to 5-fold higher than in single agent studies of ONT-093. Conclusions: Doses of ONT-093 achieving serum concentrations associated with biological activity were well tolerated in combination with standard doses of paclitaxel. Toxicities of the combination in this schedule were mainly attributable to paclitaxel and dose-limiting toxicity was limited to febrile neutropenia. There was an apparent pharmacokinetic interaction between paclitaxel and ONT-093, possibly related in part to the excipient, Cremophor, present in the paclitaxel formulation.
- Published
- 2005
- Full Text
- View/download PDF
30. Antisense approaches in prostate cancer
- Author
-
Chi, Kim N and Gleave, Martin E
- Abstract
Patients with hormone refractory prostate cancer have limited treatment options and new therapies are urgently needed. Advances in the understanding of the molecular mechanisms implicated in prostate cancer progression have identified many potential therapeutic gene targets that are involved in apoptosis, growth factors, cell signalling and the androgen receptor (AR). Antisense oligonucleotides are short sequences of synthetic modified DNA that are designed to be complimentary to a selected gene’s mRNA and thereby specifically inhibit expression of that gene. The antisense approach continues to hold promise as a therapeutic modality to target genes involved in cancer progression, especially those in which the gene products are not amenable to small molecule inhibition or antibodies. The current status and future direction of a number of antisense oligonucleotides targeting several genes, including BCL-2, BCL-XL, clusterin, the inhibitors of apoptosis (IAP) family, MDM2, protein kinase C-alpha, c-raf, insulin-like growth factor binding proteins and the AR, that have potential clinical use in prostate cancer are reviewed.
- Published
- 2004
- Full Text
- View/download PDF
31. Asian Race and Impact on Outcomes After Radical Radiotherapy for Localized Prostate Cancer
- Author
-
MAN, ADA, PICKLES, TOM, and CHI, KIM N.
- Abstract
We compared survival outcomes in patients of Asian descent treated with curative intent radiation therapy for prostate cancer with that in the nonAsian population in British Columbia, Canada.
- Published
- 2003
- Full Text
- View/download PDF
32. Metastatic Large-Cell Neuroendocrine Prostate Carcinoma: Successful Treatment With Androgen Deprivation Therapy
- Author
-
Azad, Arun A., Jones, Edward C., and Chi, Kim N.
- Published
- 2014
- Full Text
- View/download PDF
33. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma
- Author
-
Bacon, Jack V.W., Annala, Matti, Soleimani, Maryam, Lavoie, Jean-Michel, So, Alan, Gleave, Martin E., Fazli, Ladan, Wang, Gang, Chi, Kim N., Kollmannsberger, Christian K., Wyatt, Alexander W., and Nappi, Lucia
- Abstract
There is a lack of molecularly-informed biomarkers for patients with metastatic renal cell carcinoma (RCC). Plasma cell-free DNA (cfDNA) sequencing is a minimally-invasive alternative to tissue for profiling the genome in other cancers but relevance in metastatic RCC remains unclear.
- Published
- 2020
- Full Text
- View/download PDF
34. A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205
- Author
-
Hotte, Sebastien J., Chi, Kim N., Joshua, Anthony M., Tu, Donsheng, Macfarlane, Robyn J., Gregg, Rirchard W., Ruether, Joseph D., Basappa, Naveen S., Finch, Daygen, Salim, Muhammad, Winquist, Eric W., Torri, Vamsee, North, Scott, Kollmannsberger, Christian, Ellard, Susan L., Eigl, Bernard J., Tinker, Anna, Allan, Alison L., Beja, Kevin, Annala, Matti, Powers, Jean, Wyatt, Alexander W., and Seymour, Lesley
- Abstract
In PTEN-loss models, the phosphatidylinositol 3-kinase (PI3K)/AKT and androgen receptor signaling pathways cross-regulate by reciprocal feedback whereby inhibition of one activates the other, creating a rationale for co-targeting. We studied the irreversible, pan-isoform inhibitor of Class I PI-3K PX-866 singly (part A) and with abiraterone acetate (AA) in patients on AA with rising prostate-specific antigen (PSA) (part B).
- Published
- 2019
- Full Text
- View/download PDF
35. Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone
- Author
-
Ryan, Charles J., Kheoh, Thian, Li, Jinhui, Molina, Arturo, De Porre, Peter, Carles, Joan, Efstathiou, Eleni, Kantoff, Philip W., Mulders, Peter F.A., Saad, Fred, and Chi, Kim N.
- Abstract
Prognostic models are needed to address the wide spectrum of clinical conditions in chemotherapy-naïve mCRPC. We developed a model that categorized patients with mCRPC treated with abiraterone acetate plus prednisone into 3 risk groups, and showed a threefold difference in progression-free survival between good versus poor risk group. With validation, this model may help guide treatment and clinical trial design.
- Published
- 2018
- Full Text
- View/download PDF
36. Hormonal therapy for prostate cancer: can bicalutamide-induced gynecomastia and breast pain be prevented?
- Author
-
Michels, Jorg and Chi, Kim N
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.